Instil Bio shares hold as JMP reiterates Market Perform rating

Instil Bio (TIL) was a key topic at the recent ASCO meeting, where analysts discussed the company's market position and recent clinical data; JMP analysts reiterated a Market Perform rating, citing fair valuation based on cash per share and platform value. H.C. Wainwright, however, raised its price target to $125 from $105 with a Buy rating, following positive Phase 1/2 data for AXN-2510 in non-small cell lung cancer, while also noting Pfizer's significant investment in bispecific antibody treatments as validation of the therapeutic area's potential.

Analysis

Instil Bio Inc. (NASDAQ:TIL) has demonstrated significant stock momentum, gaining 28% in the past week and 41% year-to-date, attracting varied analyst attention following the 2025 ASCO Annual Meeting. JMP analysts maintained a Market Perform rating, predicated on a valuation considering cash per share and platform value. In contrast, H.C. Wainwright analyst Mitchell Kapoor upgraded Instil Bio's price target from $105 to $125 and reiterated a Buy rating, citing positive Phase 1/2 data for its non-small cell lung cancer treatment, AXN-2510, which showed a 23% overall response rate. This bullish stance is further supported by the broader industry validation of PD-1/L1 x VEGF bispecific antibodies, exemplified by Pfizer's potential $6.05 billion investment in 3SBio’s candidate, a factor H.C. Wainwright noted as influencing their revised target. Discussions at ASCO highlighted the PD-(L)1xVEGF bispecific antibody landscape, with Dr. Ford noting that progression-free survival results from Summit's recent data were a "resounding success" and an overall survival hazard ratio below 0.8 is clinically significant, providing benchmarks for the field. While InvestingPro's average analyst price target suggests significant upside, its Fair Value analysis indicates the stock is fairly valued, presenting a mixed quantitative outlook. The per-ticker sentiment for TIL is notably high at 0.8, reflecting recent positive developments.

Key Decisions for Investors

• Investors should carefully consider the divergent analyst perspectives, weighing H.C. Wainwright's Buy rating and $125 price target, driven by promising AXN-2510 data, against JMP's Market Perform stance and InvestingPro's fair valuation assessment.
• Monitor future clinical trial results and data releases for AXN-2510, as its 23% overall response rate in Phase 1/2 is a key positive catalyst and further progress will be critical for sustaining momentum in the competitive bispecific antibody space.
• Factor in the substantial year-to-date stock appreciation of 41% and the broader market validation for PD-1/L1 x VEGF bispecifics, as highlighted by Pfizer's major investment, when evaluating the risk-reward profile for Instil Bio.